Written by Dan Cohen and Scott Matusow Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in …
The Good: Oppenheimer Sees Celsion Corporation Shares Soaring About 180% Over 12 Months It can be tricky putting a price tag on a …
Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders were met with a rude awakening when the firm’s lead ALS asset failed to meet the primary endpoint in …
Look out for the Street’s bearish stampede today where CYTK shares are crashing 31% in the aftermath of lead drug tirasemtiv’s failure.
Cytokinetics, Inc. (NASDAQ:CYTK) investors hit the panic button following the news that the drug maker is discontinuing development of tirasemtiv for amyotrophic lateral sclerosis …
Cytokinetics, Inc. (NASDAQ:CYTK) announced that its first Phase 2 clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with …
In a research report released yesterday, MLV analyst George Zavoico upgrades shares of Cytokinetics (NASDAQ:CYTK) from a Hold to a Buy rating and increased his …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a $13 price target, which represents a potential upside of 233% …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a price target of $13, as the company provided an update regarding its cardiac …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics Inc. (CYTK) with a $13 price target, following CYTK’s second quarter earnings …
